Trials / Terminated
TerminatedNCT05369832
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical Practice
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Specified dose on specified days |
Timeline
- Start date
- 2022-12-16
- Primary completion
- 2025-01-21
- Completion
- 2025-04-11
- First posted
- 2022-05-11
- Last updated
- 2026-02-10
- Results posted
- 2026-02-10
Locations
85 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05369832. Inclusion in this directory is not an endorsement.